Peroxisome proliferator-activated receptors in atherosclerosis and inflammation - An update

被引:31
作者
Elangbam, CS [1 ]
Tyler, RD [1 ]
Lightfoot, RM [1 ]
机构
[1] Glaxo Wellcome Inc, Dept Pathol, Res Triangle Pk, NC 27709 USA
关键词
adipocyte differentiation; atherosclerosis; chemokines; cytokines; inflammation; nuclear receptors; peroxisome proliferator-activated receptors;
D O I
10.1080/019262301317052495
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor subfamily of transcription factors with pleiotropic effects on intra- and extracellular lipid metabolism, glucose homeostasis, cell proliferation, control of inflammation, and atherosclerosis. Three PPARs, namely alpha, delta, and gamma have been identified with distinct tissue distribution patterns and metabolic functions. PPAR-alpha is predominantly expressed in brown adipose tissue, liver, kidney, duodenum, heart, skeletal muscle, and vascular endothelial cells and is involved in the control of lipoprotein metabolism, fatty acid oxidation, and the cellular uptake of fatty acids. PPAR-gamma is highly expressed in brown and white adipose tissues and. to lesser extent, in large intestine, retina, and some parts of the immune system, and plays a critical role in adipocyte differentiation and fat deposition. PPAR-delta shows a widespread tissue distribution but its regulation and functions are not yet known. Considerable evidence indicates that PPARs (PPAR-a and PPAR-gamma) have beneficial effects in inflammatory diseases, including atherosclerosis, through regulation of cytokine production, adhesion molecule expression on the endothelial cells, fibrinolysis, and modulation of monocyte-derived macrophages. In this review, the general and specific roles of the PPAR isotypes and their implications in the control of vascular inflammation and atherosclerosis are discussed.
引用
收藏
页码:224 / 231
页数:8
相关论文
共 79 条
[51]   Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions [J].
Michalik, L ;
Wahli, W .
CURRENT OPINION IN BIOTECHNOLOGY, 1999, 10 (06) :564-570
[52]   Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency [J].
Miles, PDG ;
Barak, Y ;
He, WM ;
Evans, RM ;
Olefsky, JM .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (03) :287-292
[53]   Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes [J].
Minamikawa, J ;
Tanaka, S ;
Yamauchi, M ;
Inoue, D ;
Koshiyama, H .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (05) :1818-1820
[54]   Effects of troglitazone on collagen accumulation and distensibility of aortic wall in prestage of non-insulin-dependent diabetes mellitus of Otsuka Long-Evans Tokushima Fatty rats [J].
Mizushige, K ;
Noma, T ;
Yao, L ;
Yu, Y ;
Kiyomoto, H ;
Hosomi, N ;
Fukui, T ;
Kimura, S ;
Abe, Y ;
Matsuo, H .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 35 (01) :150-155
[55]   Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor α and γ activators in a tissue- and inducer-specific manner [J].
Motojima, K ;
Passilly, P ;
Peters, JM ;
Gonzalez, FJ ;
Latruffe, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (27) :16710-16714
[56]   Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells [J].
Murao, K ;
Imachi, H ;
Momoi, A ;
Sayo, Y ;
Hosokawa, H ;
Sato, M ;
Ishida, T ;
Takahara, J .
FEBS LETTERS, 1999, 454 (1-2) :27-30
[57]  
NAG B, 2000, 60 SCI SESS AM DIAB
[58]   Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ [J].
Nagy, L ;
Tontonoz, P ;
Alvarez, JGA ;
Chen, HW ;
Evans, RM .
CELL, 1998, 93 (02) :229-240
[59]  
NAITOH T, 2000, 60 SCI SESS AM DIAB
[60]   Fibrous cap formation or destruction - the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation [J].
Newby, AC ;
Zaltsman, AB .
CARDIOVASCULAR RESEARCH, 1999, 41 (02) :345-360